Florian van Bömmel

6.2k total citations
97 papers, 2.5k citations indexed

About

Florian van Bömmel is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Florian van Bömmel has authored 97 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Hepatology, 77 papers in Epidemiology and 10 papers in Infectious Diseases. Recurrent topics in Florian van Bömmel's work include Hepatitis C virus research (71 papers), Hepatitis B Virus Studies (61 papers) and Liver Disease Diagnosis and Treatment (54 papers). Florian van Bömmel is often cited by papers focused on Hepatitis C virus research (71 papers), Hepatitis B Virus Studies (61 papers) and Liver Disease Diagnosis and Treatment (54 papers). Florian van Bömmel collaborates with scholars based in Germany, Italy and Netherlands. Florian van Bömmel's co-authors include Thomas Berg, Bertram Wiedenmann, Christoph Sarrazin, A Bergk, Heiner Wedemeyer, D Hüppe, Bernd Möller, Heinz‐Hubert Feucht, Stefan Mauss and Ulrich Spengler and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Florian van Bömmel

84 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Florian van Bömmel Germany 24 2.2k 2.2k 350 96 84 97 2.5k
Janusz Cianciara Poland 12 1.3k 0.6× 1.4k 0.6× 231 0.7× 49 0.5× 48 0.6× 33 1.5k
Selim Karayalçın Türkiye 19 860 0.4× 904 0.4× 133 0.4× 40 0.4× 74 0.9× 45 1.2k
Maria Eliana Lai Italy 22 1.1k 0.5× 1.1k 0.5× 110 0.3× 69 0.7× 131 1.6× 44 2.0k
Nasser Semmo Switzerland 19 672 0.3× 830 0.4× 144 0.4× 298 3.1× 110 1.3× 61 1.2k
Magali Bouvier‐Alias France 21 1.2k 0.6× 1.3k 0.6× 364 1.0× 51 0.5× 75 0.9× 49 1.6k
Mei-Hsiu Ling United States 5 1.3k 0.6× 1.4k 0.7× 147 0.4× 66 0.7× 80 1.0× 7 1.6k
Ulrike Mihm Germany 15 635 0.3× 680 0.3× 137 0.4× 49 0.5× 67 0.8× 42 850
Kei Fujiwara Japan 17 721 0.3× 717 0.3× 136 0.4× 31 0.3× 186 2.2× 66 978
S. Hadziyannis Greece 18 1.0k 0.5× 981 0.5× 87 0.2× 26 0.3× 53 0.6× 55 1.2k
A Coutellier France 15 1.1k 0.5× 934 0.4× 459 1.3× 143 1.5× 102 1.2× 33 1.7k

Countries citing papers authored by Florian van Bömmel

Since Specialization
Citations

This map shows the geographic impact of Florian van Bömmel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florian van Bömmel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florian van Bömmel more than expected).

Fields of papers citing papers by Florian van Bömmel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florian van Bömmel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florian van Bömmel. The network helps show where Florian van Bömmel may publish in the future.

Co-authorship network of co-authors of Florian van Bömmel

This figure shows the co-authorship network connecting the top 25 collaborators of Florian van Bömmel. A scholar is included among the top collaborators of Florian van Bömmel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florian van Bömmel. Florian van Bömmel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Phan, Minh D., Burcin Özdirik, Hilmar Berger, et al.. (2025). Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma. Liver International. 45(6). e70121–e70121. 1 indexed citations
3.
Agarwal, Kosh, Marı́a Buti, Florian van Bömmel, et al.. (2024). JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2. Journal of Hepatology. 81(3). 404–414. 22 indexed citations
4.
Feld, Jordan J., André Boonstra, Sylvia M. Brakenhoff, et al.. (2024). Early HBcrAg and Anti‐HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation—A Pooled Analysis of Two Clinical Trials. Alimentary Pharmacology & Therapeutics. 61(3). 570–578. 2 indexed citations
5.
Ebel, Sebastian, Florian Lordick, Dirk Forstmeyer, et al.. (2024). The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology. 150(2). 81–81. 1 indexed citations
6.
7.
Bantel, Heike, Marcos Girala, Matthias P. Ebert, et al.. (2024). Evaluation of four chatbots in autoimmune liver disease: A comparative analysis. Annals of Hepatology. 30(1). 101537–101537. 6 indexed citations
8.
Fischer, Janett, Tobias Müller, R Heyne, et al.. (2023). Sex‐differences in the association of interleukin‐10 and interleukin‐12 variants with the progression of hepatitis B virus infection in Caucasians. Hepatology Research. 53(12). 1156–1168.
9.
Roade, Luisa, Mar Riveiro‐Barciela, Maria Pfefferkorn, et al.. (2023). HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers. JHEP Reports. 5(10). 100842–100842. 2 indexed citations
10.
11.
Fischer, Janett, Sebastian Ebel, Thomas Lincke, et al.. (2022). The Liver Maximum Capacity Test (LiMAx) Is Associated with Short-Term Survival in Patients with Early Stage HCC Undergoing Transarterial Treatment. Cancers. 14(21). 5323–5323. 3 indexed citations
12.
Ebel, Sebastian, Martin Reinhardt, Manuel F. Struck, et al.. (2022). Analysis of patient’s X-ray exposure in hepatic chemosaturation procedures: a single center experience. BMC Medical Imaging. 22(1). 165–165.
13.
Maier, Melanie, Janett Fischer, Mario Hönemann, et al.. (2022). Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection. Pathogens. 11(5). 517–517. 19 indexed citations
14.
Fischer, Janett, Tobias Müller, R Heyne, et al.. (2022). Association of Common Polymorphisms in the Interleukin-1 Beta Gene with Hepatocellular Carcinoma in Caucasian Patients with Chronic Hepatitis B. Pathogens. 12(1). 54–54. 5 indexed citations
15.
16.
Pfefferkorn, Maria, Stephan Böhm, Danilo Deichsel, et al.. (2020). Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. Journal of Hepatology. 74(2). 283–292. 43 indexed citations
17.
Brakenhoff, Sylvia M., Robert A. de Man, André Boonstra, et al.. (2020). Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. Alimentary Pharmacology & Therapeutics. 53(2). 314–320. 14 indexed citations
18.
Mihm, Ulrike, Christoph Sarrazin, Maria–Christina Jung, et al.. (2019). Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections. European Journal of Gastroenterology & Hepatology. 31(7). 845–852. 4 indexed citations
19.
Reijnders, Jurriën G.P., Katja Deterding, Jörg Petersen, et al.. (2010). Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues. Journal of Hepatology. 52(4). 493–500. 85 indexed citations
20.
Erhardt, Andreas, Thomas Göbel, George Lau, et al.. (2009). Response to antiviral treatment in patients infected with hepatitis B virus genotypes E–H. Journal of Medical Virology. 81(10). 1716–1720. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Janusz Cianciara Breakdown of academic impact, for papers by Selim Karayalçın Breakdown of academic impact, for papers by Maria Eliana Lai Breakdown of academic impact, for papers by Nasser Semmo Breakdown of academic impact, for papers by Magali Bouvier‐Alias Breakdown of academic impact, for papers by Mei-Hsiu Ling Breakdown of academic impact, for papers by Ulrike Mihm Breakdown of academic impact, for papers by Kei Fujiwara Breakdown of academic impact, for papers by S. Hadziyannis Breakdown of academic impact, for papers by A Coutellier
Rankless by CCL
2026